# A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea

> **NCT06555432** · — · RECRUITING · sponsor: **Takeda** · enrollment: 168 (estimated)

## Conditions studied

- Cytomegalovirus (CMV)

## Interventions

- **DRUG:** LIVTENCITY

## Key facts

- **NCT ID:** NCT06555432
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-14
- **Primary completion:** 2028-10-01
- **Final completion:** 2028-10-01
- **Target enrollment:** 168 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06555432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06555432, "A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South Korea". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06555432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*